Quality of life in prostate cancer survivors in developing countries: The case of the Gaza Strip, Palestine
Background & Aim: Prostate cancer is one of the most common cancers in males and the second leading cause of cancer-related deaths in Palestine. Although, many studies were conducted in de- veloped countries to evaluate quality of life (QOL) in survivors of prostate cancer, the researchers could not find any study that was conducted in a developing country including Palestine. Therefore, the purpose of this study was to evaluate the QOL of prostate cancer survivors residing in Gaza Strip, Palestine, as an example of a developing country, and compare it with the literature.
Methods & Materials: A total of a 121 men who were diagnosed with prostate cancer and live in Gaza Strip participated in this cross-sectional study. The University of California at Los Angeles Prostate-Specific Index including the RAND 36-Item Health Survey v2 was used to assess QOL of participants.
Results: Age of participants’ ranged between 52 and 89 years with a mean of 71.80 (SD 7.66). The greatest majority of participants (n = 94, 77.67%) were diagnosed with prostate cancer after the age of 60. The mean scores for the entire general QOL items was 47.93 (SD = 22.46) and the mean for all Prostate Cancer Index - University of California items was 44.20 (SD = 16.16).
Conclusion: Prostate cancer survivors living in Gaza Strip, Palestine have lower level of QOL than their counterparts who live in developed courtiers. These differences could be related to early screening and advanced technology used to treat prostate cancer in developed countries. Health care providers and health care policy makers need to improve provided health care services and introduce screening method to diagnose prostate cancer early. Further studies are recommended to compare QOL of prostate cancer survivors living in developing countries and developed countries.
American Cancer Society. Global cancer facts & figures [Online]. [cited 2007]; Available from: URL: http://www.cancer.org/acs/groups/content/@ nho/documents/document/globalfactsandfig ures2007rev2p.pdf
State of Palestine Ministry of Health. Annu- al Report 2006 [Online]. [cited 2006]; Available from: URL: http://www.moh.ps/?lang=1&page=4&id=1 42
Najjar K, Awad R, Thabet K. Cancer 1995- 2000: Palestine. State of Palestine: Ministry of Health: 2002.
Hoff B, Pow-Sang JM. Observation in the management of localized prostate cancer. Cancer Control 2001; 8(2): 151-4.
American Cancer Society. Prostate cancer overview [Online]. [cited 2014 Feb 25]; Available from: URL: http://www.cancer.org/cancer/prostatecancer /overviewguide/prostate-cancer-overview- what-is-prostate-cancer
American Cancer Society. Cancer facts & figures 2007 [Online]. [cited 2007]; Availa- ble from: URL: http://www.cancer.org/acs/groups/content/@ nho/documents/document/caff2007pwsecure dpdf.pdf
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62(4): 220-41.
Albaugh J, Hacker ED. Measurement of quality of life in men with prostate cancer. Clin J Oncol Nurs 2008; 12(1): 81-6.
Ferrans CE. Development of a conceptual model of quality of life. Sch Inq Nurs Pract 1996; 10(3): 293-304.
Litwin MS. Measuring health related quality of life in men with prostate cancer. J Urol 1994; 152(5 Pt 2): 1882-7.
Ware JE, Jr. SF-36 health survey update. Spine (Phila Pa 1976) 2000; 25(24): 3130-9.
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized pros- tate cancer. JAMA 1995; 273(2): 129-35.
Lubeck DP, Litwin MS, Henning JM, Car- roll PR. Measurement of health-related qual- ity of life in men with prostate cancer: the CaPSURE database. Qual Life Res 1997; 6(5): 385-92.
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36(7): 1002-12.
Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life as- sessment among men treated for prostate cancer. J Clin Oncol 1999; 17(9): 2882-8.
Litwin MS, McGuigan KA, Shpall AI, Dhanani N. Recovery of health related quali- ty of life in the year after radical prostatecto- my: early experience. J Urol 1999; 161(2): 515-9.
Saigal CS, Gornbein J, Reid K, Litwin MS. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Qual Life Res 2002; 11(5): 405-14.
Kim HS, Schwartz-Barcott D, Holter IM, Lorensen M. Developing a translation of the McGill pain questionnaire for cross-cultural comparison: an example from Norway. J Adv Nurs 1995; 21(3): 421-6.
Polit DF, Beck CT. The content validity in- dex: are you sure you know what's being re- ported? Critique and recommendations. Res Nurs Health 2006; 29(5): 489-97.
Munro BH. Statistical methods for health care research. 3rd ed. Philadelphia, PA: Lip- pincott Williams & Wilkins; 1997.
Korfage IJ, Essink-Bot ML, Madalinska JB, Kirkels WJ, Litwin MS, de Koning HJ. Measuring disease specific quality of life in localized prostate cancer: the Dutch experi- ence. Qual Life Res 2003; 12(4): 459-64.
Gacci M, Livi L, Paiar F, Detti B, Litwin MS, Bartoletti R, et al. Quality of life after radical treatment of prostate cancer: valida- tion of the Italian version of the University of California-Los Angeles Prostate Cancer Index. Urology 2005; 66(2): 338-43.
Ishihara M, Suzuki H, Akakura K, Komiya A, Imamoto T, Tobe T, et al. Baseline health-related quality of life in the manage- ment of prostate cancer. Int J Urol 2006; 13(7): 920-5.
Jayadevappa R, Chhatre S, Whittington R, Bloom BS, Wein AJ, Malkowicz SB. Health-related quality of life and satisfaction with care among older men treated for pros- tate cancer with either radical prostatectomy or external beam radiation therapy. BJU Int 2006; 97(5): 955-62.
Arredondo SA, Latini DM, Sadetsky N, Kawakami J, Pasta DJ, DuChane J, et al. Quality of life for men receiving a second treatment for prostate cancer. J Urol 2007; 177(1): 273-8.
Namiki S, Ishidoya S, Saito S, Satoh M, Tochigi T, Ioritani N, et al. Natural history of voiding function after radical retropubic prostatectomy. Urology 2006; 68(1): 142-7.
Shikanov SA, Eng MK, Bernstein AJ, Katz M, Zagaja GP, Shalhav AL, et al. Urinary 61 and sexual quality of life 1 year following robotic assisted laparoscopic radical prosta- tectomy. J Urol 2008; 180(2): 663-7.
Wakatsuki M, Tsuji H, Ishikawa H, Yanagi T, Kamada T, Nakano T, et al. Quality of life in men treated with carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72(4): 1010-5.
Karakiewicz PI, Kattan MW, Tanguay S, Elhilali MM, Bazinet M, Scardino PT, et al. Cross-cultural validation of the UCLA pros- tate cancer index. Urology 2003; 61(2): 302-7.
Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of dis- ease-specific and generic utility instruments in prostate cancer patients. Qual Life Res 2007; 16(3): 509-22.
Wootten AC, Burney S, Foroudi F, Fryden- berg M, Coleman G, Ng KT. Psychological adjustment of survivors of localised prostate cancer: investigating the role of dyadic ad- justment, cognitive appraisal and coping style. Psychooncology 2007; 16(11): 994-1002.
Inoue S, Shiina H, Hiraoka T, Wake K, Su- mura M, Honda S, et al. Five-year longitu- dinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures. BJU Int 2009; 104(8): 1077-84.
Berge V, Baco E, Dahl AA, Karlsen SJ. Health-related quality of life after salvage high-intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer. Int J Urol 2011; 18(9): 646-51.
Smith DS, Carvalhal GF, Schneider K, Kry- giel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer 2000; 88(6): 1454-63.
Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, et al. Pathologic features of prostate cancer found at population-based screening with a four- year interval. J Natl Cancer Inst 2001; 93(15): 1153-8.
Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population- based study of biennial screening using se- rum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100(7): 1397-405.
Sheinfeld GS, Gauthier J, Hay J, Miles A, Wardle J. Cancer screening and aging: re- search barriers and opportunities. Cancer 2008; 113(12 Suppl): 3493-504.
Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, et al. Second round results of the Finnish population- based prostate cancer screening trial. Clin Cancer Res 2004; 10(7): 2231-6.
Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171(4): 1513-9.
Kakehi Y, Kamoto T, Ogawa O, Arai Y, Litwin MS, Suzukamo Y, et al. Develop- ment of Japanese version of the UCLA Pros- tate Cancer Index: a pilot validation study. Int J Clin Oncol 2002; 7(5): 306-11.
Secchi G, Strepparava MG. The quality of life in cancer patients: a cognitive approach. Eur J Intern Med 2001; 12(1): 35-42.
Green AL, McSweeney J, Ainley K, Bryant J.Comparing parents' and children's views of children's quality of life after heart trans- plant. J Spec Pediatr Nurs 2009; 14(1): 49-58.
|Issue||Vol 1 No 2 (2014): Spring|
|prostate cancer health-related quality of life developing country Gaza Strip Palestine|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|